Skip to main content
Fig. 5 | Cardiovascular Diabetology

Fig. 5

From: Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants

Fig. 5

Subgroup analysis of forest plot of HR for NOAC vs. warfarin among non-valvular AF patients with concomitant DM after PSSW. In general, the subgroup analysis showed consistent results for MACE, MALE, and major bleeding for NOACs vs. warfarin among those patients with ≥ 75 years of age, the presence of chronic kidney disease (CKD), ischemic heart disease (IHD), peripheral artery disease (PAD), and use of concomitant antiplatelet agent (APT) as the main analysis. Furthermore, NOAC reduced MACE more in diabetic AF patients with a high atherosclerotic burden including elderly, the presence of IHD or PAD. Abbreviations: APT antiplatelet agent, CKD chronic kidney disease, IHD ischemic heart disease, PAD peripheral artery disease. Other abbreviations as in Fig. 3

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840